Needham Upgrades Rocket Pharmaceuticals to Buy, Announces $9 Price Target

Benzinga Newsdesk www.benzinga.com Positive 62.2%

Neg 0% Neu 0% Pos 62.2%

Needham analyst Gil Blum upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Hold to Buy and announces $9 price target.

Comments

No comments yet. Be the first!